| ₹ crore | Q1 FY27 | Q1 FY26 | Change |
|---|---|---|---|
| Revenue | 338 | 377 | −10.4% |
| EBITDA | 50.8 | 73.2 | −30.6% |
| EBITDA margin | 15.0% | 19.4% | −4.4 pts |
| Profit before tax | 48.3 | 57.9 | −16.6% |
| Net profit | 37.2 | 39.7 | −6.1% |
| EPS | ₹22.40 | ₹95.45 | −76.5% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 1,576 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 272 | 272 | 286 | 125 | 48.6 | ||
| 1.2 | 1.2 | 85.2 | 80.5 | 27.9 | ||
| 1,305 | — | — | — | — | ||
| 1,203 | 1,242 | 1,173 | 1,045 | 1,234 | ||
| — | +5.9% | +12.3% | −15.4% | — | ||
| 177 | 199 | 175 | 117 | 197 | ||
| 14.7% | 16.0% | 14.9% | 11.2% | 16.0% | ||
| 150 | 173 | 148 | 91.5 | 171 | ||
| 140 | 146 | 141 | 95.5 | 125 | ||
| 11.6% | 11.7% | 12.0% | 9.1% | 10.1% | ||
| ₹84.14 | ₹87.67 | ₹84.78 | ₹57.46 | ₹74.97 | ||
| — | +3.4% | +47.5% | −23.4% | — | ||
| — | 132 | 172 | 41.1 | 213 | ||
| — | −73.5 | −35.7 | −27.1 | −23.5 | ||
| 58.5 | 58.5 | 136 | 14.0 | 190 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 1,576.0 | |
| - Cash, Equiv & ST Investments | 48.6 | 124.6 | 285.5 | 272.3 | 272.3 | |
| + Total Debt | 27.9 | 80.5 | 85.2 | 1.2 | 1.2 | |
| Enterprise Value | — | — | — | — | 1,304.9 | |
| Revenue | 1,234.3 | 1,044.6 | 1,173.0 | 1,241.8 | 1,202.6 | |
| Growth %, YoY | — | -15.4 | +12.3 | +5.9 | — | |
| EBITDA | 197.3 | 117.3 | 174.9 | 199.1 | 176.7 | |
| Margin % | 15.99 | 11.23 | 14.91 | 16.03 | 14.69 | |
| EBIT | 171.3 | 91.5 | 147.9 | 172.8 | 149.7 | |
| Net Income | 124.6 | 95.5 | 140.9 | 145.7 | 139.9 | |
| Margin % | 10.10 | 9.14 | 12.01 | 11.73 | 11.63 | |
| EPS, Adj (current shares) | 74.97 | 57.46 | 84.78 | 87.67 | 84.14 | |
| Growth %, YoY | — | -23.4 | +47.5 | +3.4 | — | |
| Cash from Operations | 213.3 | 41.1 | 172.0 | 132.0 | — | |
| Capital Expenditures | -23.5 | -27.1 | -35.7 | -73.5 | — | |
| Free Cash Flow | 189.8 | 14.0 | 136.3 | 58.5 | 58.5 | |
Prices at the 29 October 2026 close · figures from the company's filings with NSE
Bharat Rasayan (NSE: BHARATRAS) had a market capitalisation of ₹1,557 crore at the 29 October 2026 close (₹936.80 a share), a PE ratio of 11.1 on the last four quarters' profit and a price-to-book ratio of 1.22. In FY26 its consolidated net profit was ₹146 crore on revenue of ₹1,242 crore; in Q1 FY27 (April–June 2026) it was ₹37.2 crore, down 6.1% year on year. Its debt-to-equity ratio was 0.00 on 31 March 2026. Promoters held 74.99% of the shares on 30 September 2026.
Bharat Rasayan's PE ratio is 11.1 at the 29 October 2026 close (₹936.80 a share): a market capitalisation of ₹1,557 crore divided by consolidated net profit of ₹140 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹146 crore) it is 10.7.
Bharat Rasayan's debt-to-equity ratio was 0.00 on 31 March 2026: borrowings of ₹1.2 crore against total equity of ₹1,275 crore. A year earlier, on 31 March 2025, it was 0.08.
Bharat Rasayan's net worth — shareholders' equity in its consolidated balance sheet — was ₹1,275 crore on 31 March 2026, up 12.8% from ₹1,130 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹1,557 crore at the 29 October 2026 close.
Bharat Rasayan's price-to-book (PB) ratio is 1.22 at the 29 October 2026 close: a market capitalisation of ₹1,557 crore divided by shareholders' equity (book value) of ₹1,275 crore on 31 March 2026. That is a book value of ₹766.95 per share against a share price of ₹936.80.
In FY26, Bharat Rasayan's return on equity (ROE) was 12.1% and its return on capital employed (ROCE) was 14.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 13.3% and ROCE 13.8%.
Bharat Rasayan's book value per share was ₹766.95 on 31 March 2026: shareholders' equity of ₹1,275 crore divided by the 1.66 crore shares in issue. The share price at the 29 October 2026 close was ₹936.80.
Bharat Rasayan's market capitalisation was ₹1,557 crore at the 29 October 2026 close: 1.66 crore shares at ₹936.80 each.
No. Bharat Rasayan had borrowings of ₹1.2 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.00. Its cash and current investments were ₹273 crore, so it held net cash of ₹271 crore.
In 2026, Bharat Rasayan has declared one dividend: ₹0.50 with record date 17 September 2026.
Bharat Rasayan's basic earnings per share (EPS) were ₹87.67 in FY26.
Promoters held 74.99% of Bharat Rasayan on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
Bharat Rasayan will announce its Q2 FY27 results (July–September 2026) on Friday, 13 November 2026, the date of the board meeting it has notified to the exchanges.
On 30 September 2026, Bharat Rasayan's shares were held by promoters 74.99%, foreign portfolio investors (FII/FPI) 0.58%, domestic institutions (DII) 1.70% (including mutual funds at 1.66%) and retail and other non-institutional investors 22.72%. Over the year, FII holding was up 0.11 percentage points from 0.47% and DII holding was down 1.05 percentage points from 2.75%.
At the 29 October 2026 closing prices, on FY26 net profit, Bharat Rasayan's PE ratio is 10.7, the lowest of the four: Insecticides 10.8, India Pesticides 10.8 and Meghmani Organics 46.6, a peer average of 22.8. Each is the company's market capitalisation at that price divided by its FY26 net profit.
In FY26, Bharat Rasayan earned net profit of ₹146 crore on revenue of ₹1,242 crore, against ₹139 crore on ₹2,140 crore for Insecticides. Bharat Rasayan's operating margin was 13.9% (Insecticides 9.0%) and its return on equity 12.1% (Insecticides 12.1%). At the 29 October 2026 close, Bharat Rasayan's market capitalisation was ₹1,557 crore against ₹1,511 crore for Insecticides, and its PE ratio on FY26 profit 10.7 against 10.8.
In FY26, Bharat Rasayan generated ₹132 crore of cash from operations and spent ₹73.5 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹58.5 crore. In FY25 it was ₹136 crore.
Bharat Rasayan's latest results are for Q1 FY27 (April–June 2026), filed on 13 August 2026: consolidated net profit ₹37.2 crore, down 6.1% from ₹39.7 crore in Q1 FY26; revenue from operations ₹338 crore, down 10.4% year on year.
In FY26 (April 2025–March 2026), Bharat Rasayan's consolidated net profit was ₹146 crore, up 3.4% from ₹141 crore in FY25, on revenue from operations of ₹1,242 crore (up 5.9%). Over three years, from FY23, net profit was up 16.9%.
On FY26 consolidated figures, against Insecticides, India Pesticides and Meghmani Organics: Bharat Rasayan's operating margin of 13.9% is the second highest of the four (Insecticides 9.0%, India Pesticides 14.4%, Meghmani Organics 2.6%; peer average 8.7%); its return on equity of 12.1% is the second highest of the four (Insecticides 12.1%, India Pesticides 12.6%, Meghmani Organics 1.9%; peer average 8.8%); its revenue growth over three years of 0.2% a year is the third highest of the four (Insecticides 5.9% a year, India Pesticides 6.1% a year, Meghmani Organics −5.2% a year; peer average 2.3% a year).
From Bharat Rasayan's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.